DUPIXENT® (dupilumab) Injection
Regeneron & Sanofi and Arnold NYC
Since 2017, DUPIXENT, a biologic therapy, has changed the treatment paradigm for appropriate patients suffering from type 2 inflammatory conditions, starting with atopic dermatitis (eczema), followed closely by asthma and nasal polyps. More recently, DUPIXENT has proven to be an effective treatment for eosinophilic esophagitis (EoE), an indication it was approved for in May 2022. Then in September 2022, DUPIXENT became the first FDA-approved therapy for prurigo nodularis (PN), the second dermatological indication for the brand.
It’s always a challenge to launch new therapies in categories with long-standing medications and patients who are often accustomed to the way they treat their condition, even when their disease is not controlled. But DUPIXENT has done this effectively; it can proudly claim to be the #1 biologic prescribed by dermatologists and allergists in the U.S.
A significant milestone occurred in June 2022, when DUPIXENT became the first biologic treatment for infants, 6-months of age and older, with uncontrolled moderate to severe eczema. This was a big moment for the brand and caregivers of very young children, delivering proven efficacy and a known safety profile for patients of almost all ages. This exciting news was featured on TikTok, the social media app reaching thousands of parents and caregivers of infants and toddlers suffering with moderate to severe eczema.
DUPIXENT has helped change the treatment paradigm in many categories in just six years and will strive to lead the way with even more anticipated indications in the coming years. In fact, its constantly evolving indications make it an adaptable and leading brand from this past year. The versatile product calls for the constant creativity of its branding teams to bring the effective medication to the many patients who need it.
As the brand continues to grow, so do its indications across diseases and conditions. Those indications include a spectrum of conditions, and can be used to treat adults and children 12 years of age and older with EoE, patients with moderate-to-severe eosinophilic or oral steroid dependent asthma that is not controlled with their current asthma medicines, adults with chronic rhinosinusitis with nasal polyposis (CRSwNP) whose disease is not controlled, and adults with PN. The brand’s story continues to evolve and contribute to better patient outcomes.
